BRUIN-MCL-321: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL) (clinicaltrials.gov) - Sep 24, 2026 - P3 | N=500 | Active, not recruiting | Sponsor: Loxo Oncology, Inc. | Trial completion date: Apr 2028 ➔ Jun 2030 | Trial primary completion date: Jan 2027 ➔ Nov 2027
Trial completion date • Trial primary completion date • Hematological Malignancies • Lymphoma • Mantle Cell Lymphoma • Oncology
|